The estimated Net Worth of Mark Guinan is at least $27.2 Milione dollars as of 24 December 2020. Mr. Guinan owns over 81,756 units of Quest Diagnostics stock worth over $23,853,243 and over the last 14 years he sold DGX stock worth over $20,087. In addition, he makes $3,316,000 as Chief Financial Officer e Executive Vice President at Quest Diagnostics.
Sign up
Mr. Guinan DGX stock SEC Form 4 insiders trading
Mark has made over 8 trades of the Quest Diagnostics stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 81,756 units of DGX stock worth $5,437,592 on 24 December 2020.
The largest trade he's ever made was exercising 81,756 units of Quest Diagnostics stock on 24 December 2020 worth over $5,437,592. On average, Mark trades about 6,148 units every 65 days since 2010. As of 24 December 2020 he still owns at least 155,335 units of Quest Diagnostics stock.
You can see the complete history of Mr. Guinan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Guinan biography
Mark J. Guinan serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Guinan joined the Company in July 2013. From 2010 until joining Quest Diagnostics in 2013, he served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the health care industry. Mr. Guinan has served as a director of Myovant Sciences, Ltd. since July 2018. Previously, he had served in a number of finance and operations roles in a long career at Johnson & Johnson including 2009 to 2010 as Vice President, Chief Procurement Officer, and 2005 to 2009 as Vice President, Group Finance Pharmaceuticals. Before joining Johnson & Johnson in 1997, he held a number of financial roles at Procter & Gamble.
What is the salary of Mark Guinan?
As the Chief Financial Officer e Executive Vice President of Quest Diagnostics, the total compensation of Mark Guinan at Quest Diagnostics is $3,316,000. There are 3 executives at Quest Diagnostics getting paid more, with Stephen Rusckowski having the highest compensation of $10,118,500.
How old is Mark Guinan?
Mark Guinan is 58, he's been the Chief Financial Officer e Executive Vice President of Quest Diagnostics since 2013. There are 11 older and 8 younger executives at Quest Diagnostics. The oldest executive at Quest Diagnostics, Inc. is Gail Wilensky, 76, who is the Independent Director.
Insiders trading at Quest Diagnostics
Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty e Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.
What does Quest Diagnostics do?
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
What does Quest Diagnostics's logo look like?
Complete history of Mr. Guinan stock trades at Hill-Rom Inc, Quest Diagnostics e Myovant Sciences Ltd
Quest Diagnostics executives and stock owners
Quest Diagnostics executives and other stock owners filed with the SEC include:
-
Stephen Rusckowski,
Chairman of the Board, President, Chief Executive Officer -
Manuel Mendez,
Executive Officer -
Stephen H. Rusckowski,
Chairman, Pres & CEO -
Mark Guinan,
Chief Financial Officer, Executive Vice President -
James Davis,
Executive Vice President, General Diagnostics -
Carrie Manner,
Senior Vice President - Advanced Diagnostics -
Catherine Doherty,
Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing -
Michael Prevoznik,
Senior Vice President, General Counsel -
James E. Davis,
Exec. VP of Gen. Diagnostics -
Carrie Eglinton Manner,
Sr. VP of Advanced Diagnostics -
Daniel Stanzione,
Lead Independent Director -
Gary Pfeiffer,
Independent Director -
Denise Morrison,
Independent Director -
Gail Wilensky,
Independent Director -
Timothy Main,
Independent Director -
Timothy Ring,
Independent Director -
Vicky Gregg,
Independent Director -
Helen Torley,
Independent Director -
Wright Lassiter,
Independent Director -
Michael E. Prevoznik,
Sr. VP & Gen. Counsel -
Mark J. Guinan,
Exec. VP & CFO -
Gary D. Samuels,
VP of Corp. Communications -
Timothy Sharpe,
VP of Compliance -
Shawn C. Bevec,
VP of Investor Relation -
Gabrielle Wolfson,
Sr. VP and Chief Information & Digital Officer -
Michael J. Deppe,
VP, Corp. Controller & Chief Accounting Officer -
Robert B Carter,
Director -
Jeffrey M Leiden,
Director -
Jenne K Britell,
Director -
Robert A Klug,
VP, Corporate Controller -
Everett Cunningham,
SVP, Commercial -
John B Ziegler,
Director -
Jon R Cohen,
SVP and Chief Medical Officer -
William F Buehler,
Director -
John B. Haydon,
SVP, Operations -
Kathy Ordonez,
SVP, Discovery & Development -
Robert Hagemann,
Corp VP & Chief Fin Officer -
Surya N Mohapatra,
President & COO -
Joan Elizabeth Miller,
Sr VP -Pathology& HospServices -
John C Md Baldwin,
Director -
Wayne R. Simmons,
Vice President, Operations -
Rosanne Haggerty,
Director -
Plc Gsk,
10% owner -
Thomas W Ii Grant,
Executive Officers -
William R Grant,
Director -
Thomas F Bongiorno,
Vice President and Controller -
James F Iii Flaherty,
Director -
David M Zewe,
Sr. VP -Diagnostic Testg Ops -
Robert E Peters,
Vice President, Sales & Mktg. -
Kenneth W/Nj Freeman,
Chairman, Chief Exec Officer -
Mary A Cirillo,
Director -
Kenneth D Brody,
Director -
Gerald C Marrone,
Sr. VP, Administration -
Luis Diaz,
Director -
Tracey Doi,
Director -
Michael J Deppe,
SVP, Corp. Controller & CAO -
Sam Samad,
Executive Vice President & CFO -
Patrick Plewman,
SVP for Diagnostic Services -
Karthik Kuppusamy,
SVP, Clinical Solutions -
J. E. Davis,
CEO and President -
Mark E Delaney,
SVP & Chief Commercial Officer -
Mark A Gardner,
SVP of Molecular Gen & Oncol